



**LIST OF ON-GOING CLINICAL TRIALS AT THE MEDICAL CITY**

**(As of October 2021)**

Title of Clinical Trial	STATUS	ClinicaTrial.gov Identifier/ PHRR NUMBER	SITE
A randomized, controlled phase 3 study in Cabozatinib (XL184) in combination with Atezolizumab versus Sorafenib in subjects with Advanced Hepatocellular Carcinoma who have not received previous systemic anticancer therapy	On-going	<a href="#">PHRR190625-002154</a>	TMC PASIG
A multi-country study on the prescription patterns of short-acting beta-2 agonist (SABA) and its potential effects on Asthma control: A cross-sectional study on SABA use in Asthma	On-going	PHRR190531-002146	TMC PASIG
A 12-week phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once monthly subcutaneous erenumab 70mg in adult chronic migraine patients	On-going	<a href="#">PHRR190620-002156</a>	TMC PASIG
A phase 3, randomized, multi-center, open-label, controlled study to evaluate the efficacy and safety of APL-2 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)	On-going	<a href="#">PHRR190808-002175</a>	TMC PASIG
Cryo AF Global Registry	On-going	<a href="#">NCT02752737</a>	TMC PASIG
An open-label, non-randomized, multi-center extension study to evaluate the long term safety and efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)	On-going	<a href="#">PHRR210625-003407</a>	TMC PASIG
A randomized, double-blind, placebo-controlled phase 3 trial of Pembrolizumab (MK-3475) versus placebo in participants with Esophageal Carcinoma receiving concurrent definitive Chemoradiotherapy (KEYNOTE 975)	On-going	<a href="#">PHRR200210-002490</a>	TMC ILOILO



<p>A three-arm, randomized, placebo-controlled, double-blind phase 3 study to evaluate the safety and efficacy of once-daily and twice-daily dosing of a Novel Hydrocortisone Acetate 90mg suppository formulation administered with the Sephure® suppository applicator in subjects with Ulcerative Colitis of the Rectum</p>	<p>On-going</p>	<p><a href="#">NCT04469686</a></p>	<p>TMC CALRK</p>
<p>A three-arm, randomized, placebo-controlled, double-blind phase 3 study to evaluate the safety and efficacy of once-daily and twice-daily dosing of a Novel Hydrocortisone Acetate 90mg suppository formulation administered with the Sephure® suppository applicator in subjects with Ulcerative Colitis of the Rectum</p>	<p>On-going</p>	<p><a href="#">NCT04469686</a></p>	<p>TMC ILOILO</p>
<p>Public Health Emergency: Solidarity Trial</p>	<p>On-going</p>	<p><a href="#">PHRR210930-003973</a></p>	<p>TMC PASIG</p>
<p>A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urticaria patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301</p>	<p>On-going</p>	<p><a href="#">PHRR200819-002796</a></p>	<p>TMC PASIG</p>
<p>A prospective, randomized, active treatment-controlled, evaluator-blinded (radiologist reviewer and physician evaluator) multicenter study to establish the superiority of a hyaluronan-based scaffold (Hyalofast®) with autologous bone marrow aspirate concentrate (BMAC) in the treatment of articular knee cartilage defect lesions in comparison to control (microfracture treatment)</p>	<p>On-going</p>	<p><a href="#">NCT02659215</a></p>	<p>TMC PASIG</p>
<p>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease</p>	<p>On-going</p>	<p><a href="#">PHRR200903-002907</a></p>	<p>TMC CALRK</p>
<p>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease</p>			<p>TMC PASIG</p>



High dose Melatonin in symptomatic, hypoxemic COVID-19 patients requiring hospitalization (MAC19 PRO): A randomized, double-blind, placebo-controlled trial	On-going	<a href="#">PHRR201223-003157</a>	TMC PASIG
A randomized, double-blind, phase 3 study of Platinum-Based Chemotherapy with or without INCMGA0012 in First-Line Metastatic Squamous and NonSquamous Non-Small Cell Lung Cancer (POD1UM-304)	On-going	<a href="#">NCT04205812</a>	TMC PASIG
An open-label, randomized phase 3 study to evaluate efficacy and safety of Pembrolizumab (MK-3475) in combination with MK-6482 and Lenvatinib (MK-7902) or MK-1308A in combination with Lenvatinib versus Pembrolizumab and Lenvatinib as firstline treatment in participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	On-going	<a href="#">PHRR210911-003887</a>	TMC PASIG
A phase III, multi-center, randomized, parallel group, double-blind, double-dummy, active controlled study of Evobrutinib compared with Teriflunomide in participants with Relapsing Multiple Sclerosis to evaluate efficacy and safety	On-going	<a href="#">NCT04338061</a>	TMC ILOILO
A phase 3 randomized, double-blind, multi-center, global study of Monalizumab or Placebo in combination with Cetuximab in patients with recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck previously treated with an Immune Checkpoint Inhibitor	On-going	<a href="#">NCT04590963</a>	TMC PASIG
DISCOVER Global Registry - Real world data on management and quality of care	On-going	<a href="#">NCT03549754</a>	TMC PASIG
A phase III, randomized, double-blind, placebo-controlled, multi-center study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in patients with Hepatocellular Carcinoma who are at high risk of recurrence after Curative Haptic Resection or Ablation (EMERALD-2)	On-going	<a href="#">NCT03847428</a> <a href="#">PHRR210310-003410</a>	TMC PASIG



<p>A randomized phase 3 study evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy alone in Cisplatin-Ineligible participants with Muscle-invasive Bladder Cancer (KEYNOTE-905/EV-303)</p>	<p>On-going</p>	<p><a href="https://clinicaltrials.gov/ct2/show/study/NCT03924895">NCT03924895</a>  <a href="https://www.fda.gov/oc/ohrt/PHRR210911-003890">PHRR210911-003890</a></p>	<p>TMC PASIG</p>
<p>A multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial of MW33 injection to evaluate the efficacy and safety in patients with mild or moderate COVID-19</p>	<p>On-going</p>	<p><a href="https://clinicaltrials.gov/ct2/show/study/NCT04627584">NCT04627584</a></p>	<p>TMC ILOILO</p>
<p>A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolocizumab 6mg compared to panretinal photocoagulation laser in patient with proliferative diabetic retinopathy (CONDOR)</p>	<p>On-going</p>	<p><a href="https://clinicaltrials.gov/ct2/show/study/NCT04278417">NCT04278417</a>  <a href="https://www.fda.gov/oc/ohrt/PHRR210216-003336">PHRR210216-003336</a></p>	<p>TMC PASIG</p>
<p>An, adaptive, randomized, double-blind, placebo-controlled Phase II/III Trial of Monoclonal Antibody SCTA01 against SARS-CoV-2 high-risk outpatients with COVID-19 (MAOP3 TRIAL)</p>	<p>On-going</p>	<p><a href="https://clinicaltrials.gov/ct2/show/study/NCT04709328">NCT04709328</a></p>	<p>TMC ILOILO</p>
<p>An adaptive, randomized, double-blind, placebo-controlled, phase II/III trial of Monoclonal Antibody SCTA01 against SARS-CoV-2 in patients with Severe COVID-19 admitted to high dependence of Intensive Care Unit (MASPS TRIAL)</p>	<p>On-going</p>	<p><a href="https://clinicaltrials.gov/ct2/show/study/NCT04683328">NCT04683328</a></p>	<p>TMC ILOILO</p>
<p>A multi-center, randomized, double-blind, placebo-controlled Phase 2/3 clinical trial to evaluate the safety and efficacy of pyronaridine-artesunate (Artecom®) in COVID-19 patients</p>	<p>On-going</p>	<p><a href="https://clinicaltrials.gov/ct2/show/study/NCT04701606">NCT04701606</a></p>	<p>TMC PASIG</p>
<p>A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Adjuvant Giredestrant compared with Physician's choice of Adjuvant Endocrine Monotherapy in patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer</p>	<p>On-going</p>	<p><a href="https://clinicaltrials.gov/ct2/show/study/NCT04961996">NCT04961996</a>  <a href="https://www.fda.gov/oc/ohrt/PHRR210930-003951">PHRR210930-003951</a></p>	<p>TMC PASIG</p>



<p>A randomized, double-blind, double dummy, parallel group, multicenter 24 to 52 week variable length study to assess the efficacy and safety of Budesonide, Glycopyrronium, and Formoterol Fumerate Metered Dose Inhaler (MDI) relative to Budesonide and Formoterol Fumerate MDI and Symbicort® pressurized MDI in adult and adolescent participants with inadequately controlled asthma (KALOS)</p>	<p>On-going</p>	<p><a href="#">NCT04609878</a>  <a href="#">PHRR210205-003330</a></p>	<p>TMC PASIG</p>
<p>A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older</p>	<p>On-going</p>	<p><a href="#">NCT04904471</a></p>	<p>TMC ILOILO</p>
<p>A global, multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy, safety and immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults aged 18 years and older</p>	<p>Active, not recruiting</p>	<p><a href="#">NCT05050474</a></p>	<p>TMC ILOILO</p>
<p>A randomized, double-blind, placebo-controlled, parallel group, phase 3, multicenter trial investigating the efficacy and safety of C21 as add on to standard of care in adult subjects with COVID-19 (ATTRACT-3)</p>	<p>On-going</p>	<p><a href="#">NCT04880642</a></p>	<p>TMC ILOILO</p>